Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

Sponsor

Fate Therapeutics (Industry)

Overall Status

Completed

CT.gov ID

NCT01527838

Collaborator

(none)

Enrollment

Locations

Arm

Duration (Months)

3.3

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial at approximately 2-4 centers within the U.S.

Condition or Disease	Intervention/Treatment	Phase
Non-Hodgkin's Lymphoma (NHL) Hodgkin's Disease Chronic Lymphocytic Leukemia (CLL) Acute Myelogenous Leukemia (AML) Acute Lymphoblastic Leukemia (ALL)	Biological: Single FT1050 treated UCB unit	Phase 1

Detailed Description

The trial will be conducted in three sequential cohorts of 6-12 evaluable subjects each.

Cohort 1 will enroll eligible subjects for whom a single CB unit has been identified that meets the minimum HLA-matching criteria and has a minimum pre-cryopreservation total nucleated cell (TNC) dose of at least 2.5 x 10^{7 cells/kg. Cohort 2 is identical to Cohort 1,
except that the TNC dose of the CB unit must be between 2.0 - <2.5 x 10}7 cells/kg. Finally, Cohort 3 is identical to Cohort 2, except that the TNC dose of the CB unit must be between 1.5 - <2.0 x 10^7 cells/kg. If no safety rules are triggered, the study will proceed to the next dosing cohort. Within a dosing cohort, no more than three subjects may be before Day 42 at any one time, unless they have already engrafted neutrophils. The final dosing cohort is defined as the last cohort where 12 evaluable subjects are treated and no stopping rules are triggered. The corresponding TNC dose level will be considered the minimally acceptable TNC dose level.

Study Design

Study Type:

Interventional

Actual Enrollment :

10 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies

Study Start Date :

Jan 1, 2012

Actual Primary Completion Date :

Oct 1, 2013

Actual Study Completion Date :

Nov 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Single FT1050 treated UCB Unit Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood	Biological: Single FT1050 treated UCB unit Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood

Arm

Intervention/Treatment

Experimental: Single FT1050 treated UCB Unit

Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood

Biological: Single FT1050 treated UCB unit

Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood

Outcome Measures

Primary Outcome Measures

Neutrophil engraftment/chimerism [Day 42]
To determine the minimally effective TNC dose for a single FT1050-treated CB unit based on neutrophil engraftment/chimerism when used for hematopoietic reconstitution following a reduced-intensity conditioning regimen for hematologic malignancies.

Secondary Outcome Measures

Safety [Day 100]
Define the safety profile of treatment with a single FT1050-treated CB unit. To define the preliminary efficacy of treatment with a single FT1050-treated CB unit.
Immune reconstitution [2 years]
To assess immune reconstitution (B-, T-, and NK-cells).
Donor search [Day 0]
To determine time from the initiation of donor search to transplantation.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects with hematologic malignancies for whom allogeneic stem cell transplantation is deemed clinically appropriate. Eligible diseases and stages include:

Non-Hodgkin's lymphoma or Hodgkin's lymphoma
Chronic lymphocytic leukemia (CLL)
Acute myelogenous leukemia (AML)
Chronic myelogenous leukemia (CML)

Lack of 5-6/6 HLA-matched related or 8/8 HLA-A, B, C, DRß1 matched unrelated donor; or unrelated donor not available within appropriate timeframe.

Identification of suitable backup CB unit(s) (single unit with pre-cryopreservation cell dose ≥ 2.5 x 10^{7 TNC/kg or two units with
pre-cryopreservation cell dose ≥ 1.5 x 10}7 TNC/kg each) and meeting minimum HLA match criteria.
An acceptable alternative to one or two backup CB unit(s) is the identification of an eligible related haploidentical donor that meets minimum HLA match criteria.

Age 18-65 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Signed IRB approved Informed Consent Form (ICF).

Exclusion Criteria:

The following hematologic malignancies are excluded:

Myelofibrosis (Agnogenic Myeloid Metaplasia)
Aplastic anemia.

Previous treatment that included an allogeneic transplant
Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular
dysfunction (Ejection fraction < 40%) as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension; history of myocardial infarction with depressed ejection fraction.
Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected DLCO of < 50% of predicted, corrected for hemoglobin.
Renal disease: serum creatinine > 2.0 mg/dl and calculated creatinine clearance < 40 mL/min
Hepatic disease: serum bilirubin > 2.0 mg/dl (except in the case of Gilbert's syndrome or ongoing hemolytic anemia), SGOT or SGPT > 3 x upper limit of normal.
Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation.
HIV antibody.
Uncontrolled infection.
Pregnancy or breast feeding mother.
Inability to comply with the requirements for care after allogeneic stem cell transplantation.
Participation in a concurrent clinical trial with a novel, unapproved investigational agent < 30 days prior to Day 0.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Massachusetts General Hospital	Boston	Massachusetts	United States	02214
2	Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program	Boston	Massachusetts	United States	02215
3	Ohio State Univeristy Comprehensive Cancer Center	Columbus	Ohio	United States	43210